跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
XOSPATA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
XOSPATA
Authorized
STANDARD
XOSPATA
astellas pharma canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
c67ae51647b8f8b6
Company
astellas pharma canada inc
Type
Standard
Approval Details
Approval Id
c67ae51647b8f8b6
Drug Approval Canada Name
XOSPATA
Product Name
XOSPATA
Status
Marketed
Status Date
2020-02-03
Original Market Date
2020-02-03
Din
02495058
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01EX13 GILTERITINIB
Atc Name
l 01 ex 13
Aig Number
0162011001
Company Name
astellas pharma canada inc
Company Address
675 Cochrane Drive, West Tower, Suite 650, Markham, Ontario, Canada, L3R 0B8
Active Ingredients
GILTERITINIB (GILTERITINIB FUMARATE)
40 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
c67ae51647b8f8b6
Type
Standard
Back to Health Canada Approvals